L-type calcium channel blocker use and proteinuria among children with chronic kidney diseases

Kelsey L. Richardson, Donald J. Weaver, Derek K. Ng, Megan K. Carroll, Susan L. Furth, Bradley A. Warady, Joseph T. Flynn

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Hypertension is common among children with chronic kidney disease (CKD), and dihydropyridine calcium channel blockers (dhCCBs) are frequently used as treatment. The impact of dhCCBs on proteinuria in children with CKD is unclear. Methods: Data from 722 participants in the Chronic Kidney Disease in Children (CKiD) longitudinal cohort with a median age of 12 years were used to assess the association between dhCCBs and log transformed urine protein/creatinine levels as well as blood pressure control measured at annual visits. Angiotensin-converting enzyme inhibitor (ACEi) and angiotensin receptor blocker (ARB) use was evaluated as an effect measure modifier. Results: Individuals using dhCCBs had 18.8% higher urine protein/creatinine levels compared to those with no history of dhCCB or ACEi and ARB use. Among individuals using ACEi and ARB therapy concomitantly, dhCCB use was not associated with an increase in proteinuria. Those using dhCCBs had higher systolic and diastolic blood pressures. Conclusions: Use of dhCCBs in children with CKD and hypertension is associated with higher levels of proteinuria and was not found to be associated with improved blood pressure control.

Original languageEnglish (US)
JournalPediatric Nephrology
DOIs
StateAccepted/In press - 2021

Keywords

  • Calcium channel blocker
  • Children
  • Chronic kidney disease
  • Hypertension
  • Proteinuria

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Nephrology

Fingerprint Dive into the research topics of 'L-type calcium channel blocker use and proteinuria among children with chronic kidney diseases'. Together they form a unique fingerprint.

Cite this